Brokerages Set Bristol Myers Squibb Company (NYSE:BMY) Target Price at $59.20

Bristol Myers Squibb Company (NYSE:BMY) has received a consensus rating of “Hold” from the twenty research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, eleven have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $59.20.

BMY has been the topic of a number of recent research reports. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. UBS Group raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price target for the company from $46.00 to $65.00 in a research note on Wednesday, January 7th. Guggenheim reaffirmed a “buy” rating and set a $72.00 price objective (up previously from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Finally, Bank of America upgraded shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their price target for the stock from $52.00 to $61.00 in a research note on Monday, December 15th.

Bristol Myers Squibb Stock Up 1.3%

BMY stock opened at $60.64 on Thursday. The company has a current ratio of 1.26, a quick ratio of 1.17 and a debt-to-equity ratio of 2.32. The firm has a 50 day simple moving average of $55.33 and a 200-day simple moving average of $49.46. The company has a market capitalization of $123.49 billion, a P/E ratio of 17.58, a PEG ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the prior year, the firm earned $1.67 EPS. The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts predict that Bristol Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BMY. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $25,000. Darwin Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth $25,000. Physician Wealth Advisors Inc. increased its position in shares of Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the period. Harbor Capital Advisors Inc. raised its stake in Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares in the last quarter. Finally, EQ Wealth Advisors LLC bought a new stake in Bristol Myers Squibb during the fourth quarter worth about $32,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.